Description

CooperCompanies’ Hidden Growth Engine — MyDay Keeps Expanding Despite Channel Pressure!

CooperCompanies reported third-quarter fiscal 2026 consolidated revenue of $1.066 billion, up 1% year-over-year on both reported and organic bases. CooperVision generated $717 million of revenue, essentially flat from a year earlier, while CooperSurgical increased 3% organically to $349 million. CooperVision was affected by deliberate reductions in U.S. channel inventory, which are expected to continue weighing on fourth-quarter results. Despite destocking, underlying U.S. consumption grew at a mid-single-digit rate, indicating relatively healthy end-market demand. EMEA and Asia Pacific trends were generally stable to improving, although Asia Pacific continues to face portfolio rationalization and weakness in China. The MyDay franchise remained a key growth driver, posting double-digit regional growth across EMEA and the Americas. Performance was supported by premium toric and multifocal lenses and the recently launched MyDay MiSight for myopia management. Biofinity remained stable in EMEA, while U.S. results were affected by inventory adjustments.